Teleflex (NYSE: TFX) has recently received a number of price target changes and ratings updates:

  • 8/9/2017 – Teleflex had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $253.00 price target on the stock, up previously from $230.00.
  • 8/9/2017 – Teleflex had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $238.00 price target on the stock, up previously from $220.00.
  • 8/8/2017 – Teleflex was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/4/2017 – Teleflex had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They wrote, “TFX’s 2Q17 revenue and EPS beat consensus. Management maintained its 2017 constant currency revenue growth guidance and raised its adjusted EPS guidance. TFX’s organic revenue growth slowed somewhat to 3.5% in 2Q17 from 4.2% in 1Q17 though we note it faced a more difficult comp. Vascular Solutions’ growth slowed to 11.5% (adjusted for selling days) in 2Q17 from 13.0% in 1Q17. TFX had mixed margin performance with its gross margin up 90 bps Y/Y but its operating margin flat Y/Y.””
  • 8/3/2017 – Teleflex had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $230.00 price target on the stock.
  • 7/31/2017 – Teleflex was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 6/26/2017 – Teleflex had its “buy” rating reaffirmed by analysts at Barclays PLC. They wrote, “Epizyme, Inc. announced today that it has expanded its clinical collaboration with Genentech, a member of the Roche Group. Under the new agreement, Tazemetostat administered in combination with atezolizumab (Tecentriq) will be evaluated in a phase Ib/II clinical study for the treatment of patients with relapsed/refractory metastatic non-small cell lung cancer (NSCLC).””
  • 6/23/2017 – Teleflex was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $228.00 price target on the stock. According to Zacks, “Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. “
  • 6/22/2017 – Teleflex was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. “

Teleflex Incorporated (TFX) opened at 204.00 on Friday. Teleflex Incorporated has a 52-week low of $136.53 and a 52-week high of $217.97. The company has a market cap of $9.19 billion, a P/E ratio of 39.01 and a beta of 1.05. The stock’s 50 day moving average price is $209.38 and its 200 day moving average price is $196.62.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.91 by $0.13. Teleflex had a return on equity of 16.12% and a net margin of 12.36%. The firm had revenue of $528.60 million during the quarter, compared to analysts’ expectations of $518.98 million. During the same quarter last year, the firm earned $1.89 earnings per share. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. Analysts expect that Teleflex Incorporated will post $8.28 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Tuesday, August 15th will be issued a $0.34 dividend. The ex-dividend date is Friday, August 11th. This represents a $1.36 annualized dividend and a dividend yield of 0.67%. Teleflex’s dividend payout ratio is presently 26.00%.

In related news, Director Stuart A. Randle sold 2,500 shares of the stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $205.67, for a total value of $514,175.00. Following the completion of the sale, the director now owns 7,532 shares of the company’s stock, valued at $1,549,106.44. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Stephen K. M.D. Klasko sold 5,200 shares of the stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $193.56, for a total value of $1,006,512.00. Following the completion of the sale, the director now directly owns 12,880 shares of the company’s stock, valued at approximately $2,493,052.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,300 shares of company stock valued at $1,643,975. Insiders own 2.39% of the company’s stock.

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.